Previous research has shown that abnormal CD36 levels play a causal role in the development of steatosis in patients with DKD and NAFLD, with CD36-deficient mice exhibiting lower hepatic and renal lipid accumulation and hepatic and renal injury compared to controls 20. This evidence concerns the gene CD36 and diabetic kidney disease.